根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易 所股票上市规则》《上市公司重大资产重组管理办法》《上市公司监管指引第 9 号——上市公司筹划和实施重大资产重组的监管要求》《公开发行证券的公司信 息披露内容与格式准则第 26 号——上市公司重大资产重组》等法律法规和规范 性文件及《公司章程》的规定，公司董事会就本次交易履行法定程序的完备性、 合规性及提交法律文件有效性，作出如下说明： 一、关于本次交易履行法定程序的完备性、合规性的说明 交易相关敏感信息的知悉范围，并严格限定本次交易相关敏感信息的知悉范围。 制作《内幕信息知情人员登记表》及《交易进程备忘录》，经相关人员签字确认 后向深圳证券交易所进行了报送。 及其摘要和本次交易需要提交的其他有关文件。 本次交易的相关议案，关联董事均已回避表决。上述议案已经公司独立董事专门 会议审议通过，并同意提交董事会审议。 审议通过了本次交易预案及相关议案。 资产框架协议》。 份购买资产暨关联交易的进展公告》。 美年大健康产业控股股份有限公司 董事会关于本次交易履行法定程序的完备性、合规性 及提交法律文件的有效性的说明 美年大健康产业控股股份有限公司（以下 ...

Core Viewpoint - The company plans to acquire significant stakes in multiple health management subsidiaries through a share issuance, which is expected to enhance its asset scale and profitability without diluting immediate returns per share [1][3]. Group 1: Transaction Details - The company intends to purchase 84% of Hengyang Meinian Health Checkup Center, 81% of Ningde Meinian Health Management, and several other stakes in various health management companies, totaling multiple acquisitions [1]. - The transaction is structured to ensure that the company's earnings per share (EPS) will not be diluted post-transaction, with projected increases in net profit attributable to the parent company [2][3]. Group 2: Measures to Mitigate Dilution Risks - The company plans to accelerate the integration of the acquired companies to enhance profitability and operational efficiency [3]. - A commitment to improve corporate governance and operational efficiency has been established, ensuring a robust management structure and clear responsibilities among various governance bodies [4]. - The company will refine its profit distribution policy to ensure fair returns to all shareholders while maintaining sustainable growth [6]. Group 3: Commitments from Stakeholders - The actual controller and senior management have issued commitments to uphold measures that protect immediate returns, ensuring no undue interference in company operations [6]. - Specific commitments include linking compensation plans to the execution of measures aimed at mitigating dilution of immediate returns [6].

Core Viewpoint - The company intends to acquire significant equity stakes in various health management and inspection centers through a share issuance, which complies with the relevant regulations of the Major Asset Restructuring Management Measures for Listed Companies [1][2][3] Group 1: Transaction Details - The company plans to purchase 84% of Hengyang Meinian Health Examination Center Co., Ltd., 81% of Ningde Meinian Health Management Co., Ltd., 75% of Yantai Meinian Health Management Co., Ltd., and several other stakes in various health management companies [1] - The transaction includes minority stakes in several subsidiaries, such as 47.37% in Zhengzhou Meijian Health Management Co., Ltd. and 49% in Guangzhou Huadu District Meinian Health Management Co., Ltd. [1] Group 2: Compliance with Regulations - The board has conducted a thorough analysis confirming that the transaction meets the conditions outlined in Article 11, Article 43, and Article 44 of the Major Asset Restructuring Management Measures [2] - The transaction does not involve any arrangements for phased issuance of shares for asset purchase, ensuring compliance with regulatory requirements [2][3] - The board believes that the transaction will not lead to significant adverse effects on competition or independence, and it can be completed within the agreed timeframe [2][3]

Core Points - The company intends to acquire significant equity stakes in multiple health management and inspection centers through a share issuance [1][2] - The board believes that the company does not fall under any prohibitive conditions outlined in the newly implemented "Regulations on the Registration Management of Securities Issuance by Listed Companies" [2] Group 1 - The company plans to purchase 84% of Hunan Meinian Health Examination Center, 81% of Ningde Meinian Health Management, 75% of Yantai Meinian Health Management, and several other stakes in various health management companies [1] - The board has conducted a thorough analysis and concluded that there are no disqualifying conditions for the share issuance, such as negative audit opinions or administrative penalties [2] - The board's assessment confirms compliance with the relevant regulations, ensuring the legitimacy of the upcoming transaction [2]

为确保本次交易顺利进行，并保障公司及股东利益，公司聘请如下中介机构 为本次交易提供服务： 美年大健康产业控股股份有限公司（以下简称"公司"或"上市公司"）拟通过 发行股份的方式购买交易对方持有的衡阳美年健康体检中心有限公司 84.00%股 权、宁德美年大健康管理有限公司 81.00%股权、烟台美年大健康体检管理有限 公司 75.00%股权、烟台美年福田健康体检管理有限公司 49.00%股权、武汉美慈 奥亚科技管理有限公司 52.81%股权、三明美年大健康管理有限公司 85.00%股权、 肥城美年健康管理有限公司 90.00%股权、德州美年大健康体检管理有限公司 管理有限公司 80.50%股权、山东美铭奥亚健康咨询有限公司 92.35%股权及控股 子公司郑州美健健康管理有限公司 47.37%少数股权、广州花都区美年大健康管 理有限公司 49.00%少数股权、安徽美欣健康管理咨询有限公司 42.46%少数股权、 淄博美年大健康管理有限公司 49.00%少数股权、吉林市昌邑区美年大健康科技 管理有限公司 48.05%少数股权（以下简称"本次交易"）。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司重 ...

Core Viewpoint - The company has disclosed the differences between the draft report and the restructuring proposal regarding the issuance of shares for asset acquisition and related transactions, highlighting updates and changes in the transaction details and risk factors [1][2][3]. Group 1: Transaction Overview - The restructuring report includes updated definitions and clarifications to aid investor understanding, as well as specific updates to the transaction plan [1]. - The report supplements the performance commitments and compensation arrangements related to the transaction [2]. Group 2: Financial and Operational Information - The report provides additional disclosures on the financial data of the target company, including major financial indicators and recent financial statements [3][4]. - It also includes information on the compliance and integrity of the transaction parties and their management over the past five years [4][5]. Group 3: Risk Factors and Compliance - The report outlines various risks associated with the transaction, including acquisition integration risks and potential dilution of immediate returns [1][6]. - New sections in the report address compliance analysis and management discussions regarding the transaction [6][7]. Group 4: Independent Opinions - The report features updated opinions from independent directors and financial advisors regarding the transaction's fairness and compliance [6][7]. - It also includes statements from legal advisors and audit institutions related to the transaction [6].

美年大健康产业控股股份有限公司 董事会关于本次交易信息公布前 20 个交易日 公司股票价格波动情况的说明 美年大健康产业控股股份有限公司（以下简称"公司"）拟通过发行股份的方 式购买交易对方持有的衡阳美年健康体检中心有限公司 84.00%股权、宁德美年 大健康管理有限公司 81.00%股权、烟台美年大健康体检管理有限公司 75.00%股 权、烟台美年福田健康体检管理有限公司 49.00%股权、武汉美慈奥亚科技管理 有限公司 52.81%股权、三明美年大健康管理有限公司 85.00%股权、肥城美年健 康管理有限公司 90.00%股权、德州美年大健康体检管理有限公司 84.00%股权、 连江美年大健康管理有限公司 82.00%股权、沂水美年大健康体检管理有限公司 健健康管理有限公司 47.37%少数股权、广州花都区美年大健康管理有限公司 大健康管理有限公司 49.00%少数股权、吉林市昌邑区美年大健康科技管理有限 公司 48.05%少数股权（以下简称"本次交易"）。 综上，在剔除大盘因素和同行业板块因素影响后，公司股价在本次重大事项 披露前 20 个交易日内累计涨跌幅未超过 20%，不存在异常波动的情况。 特此说 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-043 第五条 公司住所：江苏省南通市人民 区华舍街道中纺时代大厦 0112 室；邮 东路 218 号；邮政编码：226008 美年大健康产业控股股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"）于 2025 年 7 月 11 日 召开第九届董事会第十次（临时）会议，审议通过《关于修订 <公司章程> 的议案》。 本议案尚需提交公司股东大会审议，同时公司董事会提请股东大会授权公司管理 层负责办理工商变更登记、备案手续等相关事项。具体变更内容以工商登记机关 核准登记内容为准。具体情况如下： 一、《公司章程》具体修订内容 修订前的条款 修订后的条款 第五条 公司住所：浙江省绍兴市柯桥 董 事 会 二〇二五年七月十二日 政编码：312030 第二百零五条 本章程以中文书写，其 第二百零五条 本章程以中文书写，其 他任何语种或不同版本的章程与本章 他任何语种或不同版本的章程与本章 程有歧义时，以在江苏省工商行政管理 程有歧义时，以在浙江省市场监督 ...

美年大健康产业控股股份有限公司 董 事 会 二〇二五年七月十一日 根据《上市规则》，上市公司董事会审议本次交易相关议案时，关联董事已 回避表决；上市公司后续在召开董事会、股东大会审议相关议案时，关联董事、 关联股东将回避表决。 特此说明。 美年大健康产业控股股份有限公司 董事会关于本次交易构成关联交易的说明 美年大健康产业控股股份有限公司（以下简称"上市公司"）拟通过发行股份 的方式购买交易对方持有的衡阳美年健康体检中心有限公司 84.00%股权、宁德 美年大健康管理有限公司 81.00%股权、烟台美年大健康体检管理有限公司 75.00% 股权、烟台美年福田健康体检管理有限公司 49.00%股权、武汉美慈奥亚科技管 理有限公司 52.81%股权、三明美年大健康管理有限公司 85.00%股权、肥城美年 健康管理有限公司 90.00%股权、德州美年大健康体检管理有限公司 84.00%股权、 连江美年大健康管理有限公司 82.00%股权、沂水美年大健康体检管理有限公司 健健康管理有限公司 47.37%少数股权、广州花都区美年大健康管理有限公司 大健康管理有限公司 49.00%少数股权、吉林市昌邑区美年大健康科技管理 ...

Core Viewpoint - The company intends to acquire significant equity stakes in multiple health management and medical examination companies through a share issuance, with a focus on ensuring the independence and fairness of the asset evaluation process [1][2][3] Group 1: Transaction Overview - The company plans to purchase 84% of Hunan Meinian Health Examination Center, 81% of Ningde Meinian Health Management, 75% of Yantai Meinian Health Management, and several other stakes in various health management companies [1] - The total stakes being acquired include significant minority interests in several companies, indicating a broad expansion strategy in the health management sector [1] Group 2: Evaluation Process - The company has engaged Jinzheng (Shanghai) Asset Appraisal Co., Ltd. as the asset evaluation agency, which is compliant with the Securities Law and has the necessary qualifications and experience [2] - The evaluation is based on a reference date of March 31, 2025, and aims to assess the total equity value of the target companies [2] Group 3: Evaluation Independence and Assumptions - The evaluation agency is independent, with no existing relationships or conflicts of interest with the company or the transaction parties, ensuring an unbiased assessment [2] - The assumptions set by the evaluation agency are reasonable and comply with national laws and market practices, reflecting the actual conditions of the assets [2] Group 4: Evaluation Methods and Fairness - The evaluation utilized both the income approach and asset-based approach, ultimately relying on the income approach for the final valuation of the equity [3] - The evaluation process adhered to principles of independence, objectivity, and fairness, resulting in a valuation that accurately reflects the market value of the assets as of the evaluation date [3] - The transaction pricing is based on the evaluation results, ensuring fairness and reasonableness, protecting the interests of the company and its minority shareholders [3]